person
as of 2026-07-01Joseph P. McEvoy, MD
Joseph P McEvoy, MDJoseph McEvoy, MD
at a glance
Roles: Principal Investigator, Study Director, Author
KOL signal score 4
1 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Duke University
Roles
Principal Investigator, Study Director, Author
KOL signal
4
Publications
1 (1 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
6
A Comparison of Long-acting Injectable Medications for Schizophrenia
NCT01136772Phase 4Completed
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
NCT00314613Phase 4Terminated
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
NCT00423878Phase 4Completed
Cardio Risk of Acute Schizophrenia Olanzapine Duke
NCT00672464Phase 4Withdrawn
Effects of Metformin and Fish Oil on Treatment With Clozapine
NCT02140788Phase 4Terminated
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
NCT00802100Phase 4Completed
Publications & congress
1
Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled Trial.
The Journal of clinical psychiatry · 2025 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR